Our Parkinson's Place: Cynapsus beefs up apomorphine oral film patent estate with deal with MonoSol Rx

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Monday, April 4, 2016

Cynapsus beefs up apomorphine oral film patent estate with deal with MonoSol Rx

April 4, 2016
Toronto, Canada

Cynapsus Therapeutics inks a global licensing agreement for certain intellectual property covering all oral films containing apomorphine for the treatment of OFF episodes in Parkinson's disease patients. The deal further strengthens the company's IP covering APL-130277, its investigational sublingual formulation of apomorphine for the treatment of OFF episodes.

Cynapsus Therapeutics (OTCQX:CYNAF) inks a global licensing agreement for certain intellectual property (IP) covering all oral films containing apomorphine for the treatment of OFF episodes in Parkinson's disease (PD) patients. The deal further strengthens the company's IP covering APL-130277, its investigational sublingual (under the tongue) formulation of apomorphine for the treatment of OFF episodes.

Under the terms of the agreement, Monosol Rx will receive an upfront payment, milestones and single-digit royalties on net sales of APL-130277.

APL-130277 is currently in Phase 3 development. The company plans to submit its New Drug Application (NDA) in the U.S. by the end of the year or early 2017.

An OFF episode, a time during which PD patients are unable to perform routine activities like eating, bathing or dressing, is thought to occur when dopamine levels in the brain fall below a certain threshold. It is considered one of the greatest unmet medical needs of PD

sufferershttp://seekingalpha.com/news/3171171-cynapsus-beefs-apomorphine-oral-film-patent-estate-deal-monosol-rx